HMGB1 is a potent trigger of arthritis - PubMed (original) (raw)
Review
HMGB1 is a potent trigger of arthritis
U Andersson et al. J Intern Med. 2004 Mar.
Free article
Abstract
Rheumatoid arthritis is a chronic inflammatory disease characterized by synovial inflammation and structural damage of joints. Although the cause of rheumatoid arthritis (RA) remains unknown, the excessive production of proinflammatory cytokines such as tumour necrosis factor (TNF) and interleukin-1 (IL-1) by intra-articular macrophages occupies a critical pathogenic role in the development and progression of the disease. High mobility group box chromosomal protein 1 (HMGB1) is a recently identified mediator of interest in human and experimental arthritides. HMGB1 can either be actively secreted from macrophages or passively released from necrotic cells of all kinds. Activated macrophages and unprogrammed cell death caused by ischaemia or activated complement are all prominent features of chronic arthritis, contributing to the persistent synovial inflammation. HMGB1 is cytoplasmically and extracellularly overexpressed in inflammatory synovial tissue in human RA as well as experimental collagen-induced arthritis. Elevated levels of HMGB1 are also present in synovial fluid samples from RA patients. Synovial tissue from rats with experimental arthritis exhibits aberrant deposition of HMGB1 preceding the onset of clinical signs of arthritis, and the expression becomes prominent after the onset of clinical disease. The synovial levels of HMGB1 are comparable with those of TNF and IL-1beta at the peak of manifest disease. HMGB1-targeted intervention with either neutralizing antibodies or the antagonistic A box domain of HMGB1 ameliorates collagen-induced arthritis both in mice and rats, and inhibits the local overexpression of IL-1beta in the joints. It is thus conceivable that therapeutic HMGB1 blockade may contribute to future treatment of human chronic arthritis.
Similar articles
- The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis.
Chen Y, Sun W, Gao R, Su Y, Umehara H, Dong L, Gong F. Chen Y, et al. Rheumatology (Oxford). 2013 Oct;52(10):1739-47. doi: 10.1093/rheumatology/ket134. Epub 2013 Apr 12. Rheumatology (Oxford). 2013. PMID: 23584368 Review. - Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study.
Sundberg E, Grundtman C, Af Klint E, Lindberg J, Ernestam S, Ulfgren AK, Harris HE, Andersson U. Sundberg E, et al. Arthritis Res Ther. 2008;10(2):R33. doi: 10.1186/ar2387. Epub 2008 Mar 17. Arthritis Res Ther. 2008. PMID: 18346273 Free PMC article. Clinical Trial. - The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor.
Biscetti F, Flex A, Pecorini G, Angelini F, Arena V, Stigliano E, Gremese E, Tolusso B, Ferraccioli G. Biscetti F, et al. Clin Exp Immunol. 2016 Apr;184(1):62-72. doi: 10.1111/cei.12758. Epub 2016 Jan 19. Clin Exp Immunol. 2016. PMID: 26671547 Free PMC article. - Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE, Tetlow LC. Woolley DE, et al. Arthritis Res. 2000;2(1):65-74. doi: 10.1186/ar70. Arthritis Res. 2000. PMID: 11219391 Free PMC article. - Exploring the therapeutic promise of targeting HMGB1 in rheumatoid arthritis.
Kaur I, Behl T, Bungau S, Kumar A, Mehta V, Setia D, Uddin MS, Zengin G, Aleya L, Arora S. Kaur I, et al. Life Sci. 2020 Oct 1;258:118164. doi: 10.1016/j.lfs.2020.118164. Epub 2020 Jul 31. Life Sci. 2020. PMID: 32739467 Review.
Cited by
- The role of high mobility group box-1 on the development of diabetes complications: A plausible pharmacological target.
Ngcobo NN, Sibiya NH. Ngcobo NN, et al. Diab Vasc Dis Res. 2024 Sep-Oct;21(5):14791641241271949. doi: 10.1177/14791641241271949. Diab Vasc Dis Res. 2024. PMID: 39271468 Free PMC article. Review. - Inhibition of ferroptosis rescues M2 macrophages and alleviates arthritis by suppressing the HMGB1/TLR4/STAT3 axis in M1 macrophages.
Feng Z, Meng F, Huo F, Zhu Y, Qin Y, Gui Y, Zhang H, Lin P, He Q, Li Y, Geng J, Wu J. Feng Z, et al. Redox Biol. 2024 Sep;75:103255. doi: 10.1016/j.redox.2024.103255. Epub 2024 Jun 24. Redox Biol. 2024. PMID: 39029270 Free PMC article. - Dichotomous roles of RIPK3 in regulating the IFN response and NLRP3 inflammasome in human monocytes.
Yang C, Yuan R, Brauner C, Du Y, Ah Kioon MD, Barrat FJ, Ivashkiv LB. Yang C, et al. J Leukoc Biol. 2023 Nov 24;114(6):615-629. doi: 10.1093/jleuko/qiad095. J Leukoc Biol. 2023. PMID: 37648661 Free PMC article. - Neuronal Death Caused by HMGB1-Evoked via Inflammasomes from Thrombin-Activated Microglia Cells.
Sheu ML, Pan LY, Yang CN, Sheehan J, Pan LY, You WC, Wang CC, Chen HS, Pan HC. Sheu ML, et al. Int J Mol Sci. 2023 Aug 11;24(16):12664. doi: 10.3390/ijms241612664. Int J Mol Sci. 2023. PMID: 37628850 Free PMC article. - The chemokine landscape: one system multiple shades.
Cecchinato V, Martini V, Pirani E, Ghovehoud E, Uguccioni M. Cecchinato V, et al. Front Immunol. 2023 May 11;14:1176619. doi: 10.3389/fimmu.2023.1176619. eCollection 2023. Front Immunol. 2023. PMID: 37251376 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials